Clinical Trials · NCT04572165
Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 194,928
- Start date
- Jan 2021
- Locations
- 1 site, Denmark
- Primary endpoint
- Occurrence of first time malignant neoplasm of pancreas